1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

  • April 2015
  • 271 pages
  • GlobalData
Report ID: 3091032


Table of Contents

Search Inside

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023


Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’s Provenge, Sanofi’s Jevtana, Johnson & Johnson’s Zytiga, Medivation/Astellas’ Xtandi, and Bayer’s Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.


Key Questions Answered

- How will prostate cancer disease management change as new agents enter the market?
- Which prostate cancer patients have the greatest unmet needs and how well will these needs be addressed by the new agents?
- What are the most dominant players in the prostate cancer space and what corporate strategies are pursued by these companies?
- What are the most promising late-stage pipeline agents for prostate cancer? How do they compare to currently marketed products?
- What opportunities will remain for future players following the launch of these pipeline agents?

Key Findings

- The prostate cancer market, in the 9MM is forecasted to rapidly increase from $2.6bn in 2013 to $8.3bn in 2023, at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer.
- GlobalData expects Medivation and Astellas’ Xtandi will become the market leader in prostate cancer. Xtandi is currently approved for pre- and post-chemotherapy metastatic castration-resistant prostate cancer (CRPC). Over the course of the forecast period, GlobalData anticipates it will receive label extensions in non-metastatic CRPC and hormone-sensitive prostate cancer, making it available to virtually all prostate cancer patients segments, with the exception of those with localized disease.
- The prostate cancer pipeline is robust with nine drugs in late-stage development. While androgen biosynthesis is still a major target, many of the pipeline candidates have diverse mechanisms of action and target proteins and pathways that are not targeted by the currently marketed prostate cancer treatments. Among these new candidates are a checkpoint inhibitor, a clusterin inhibitor, and an anti-angiogenic agent. There are also several vaccines, both autologous and off-the-shelf, that have a significant presence in this pipeline.


- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical staging, symptoms, prognosis, quality of life, and disease management.
- Annualized prostate cancer therapeutics market revenue from 2013-2023. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the prostate cancer therapeutics market.
- Pipeline analysis: The prostate cancer pipeline is robust with many late-stage candidates set to launch in the forecast period. Comprehensive analysis of the nine most promising candidates in Phase III development are highlighted and profiled.
- Analysis of the current and future market competition in the global prostate cancer therapeutics market, including insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 9MM prostate cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 9MM prostate cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility ...

Radiotherapy Market by Type, Internal & Systemic, Product, Application, End User, and Region - Global Forecasts to 2022

  • $ 5650
  • Industry report
  • June 2017
  • by MarketsandMarkets

“Radiotherapy market projected to grow at a CAGR of 6.8%.” The global radiotherapy market is expected to reach USD 9.47 billion by 2022 from USD 6.81 billion in 2017, at a CAGR of 6.8%. The rapidly ...

Prostate Cancer Therapeutics - Global Market Outlook (2017-2023)

  • $ 4157
  • Industry report
  • June 2017
  • by Stratistics MRC

According to Stratistics MRC, the Global Prostate Cancer Therapeutics market is estimated at $XX million in 2016 and is expected to reach $XX million by 2023 growing at a CAGR of XX% from 2016 to 2023. ...

Global Alpha Emitters Market

July 2017 $ 4250

Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • September 2017
    7 pages
  • Hormone  



  • Pakistan  

    United States  

View report >

Prostate Cancer Statistics in Sweden

  • September 2017
    8 pages
  • Prostate Cancer  

  • Sweden  

View report >

Prostate Cancer Statistics in the US

  • September 2017
    4 pages
  • Prostate Cancer  


  • United States  

View report >

Cancer Statistics

16 days ago

Related Market Segments :

Prostate Cancer


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.